Fulcrum Therapeutics Inc. (FULC)
NASDAQ: FULCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
FULC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $286.11M
- EPS (TTM)
- -$1.23
- Dividend yield
- None
- 52-week range
- 2.83 – 15.74
- Day range
- 3.66 – 3.78
- Volume / Avg
- 2.63M / 1.54M
- Beta
- —
- Shares outstanding
- 76.30M
- Next earnings
- Nov 4, 2026
52-week range
FULC stock today
Fulcrum Therapeutics (FULC) closed at $3.75 on Oct 8, up 2.18% (+$0.08), versus the S&P 500's 0.47% decline. At this level, FULC sits near the bottom of its 52-week range of $2.83 to $15.74: 76.2% below the high, set on Dec 8, 2025 and 32.5% above the low. FULC is down 66.8% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 61.1%.
Fulcrum Therapeutics has posted a net loss over the last twelve months (EPS of -$1.23), so its P/E ratio is not meaningful. Fulcrum Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Fulcrum Therapeutics
Company profileFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Alexander C. Sapir
- Headquarters
- Cambridge, MA
- Employees
- 9
- IPO year
- 2019
- Website
- fulcrumtx.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$3.67-2.13%
- Strong buy 0
- Buy 0
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.10
FULC news
All FULC newsFulcrum Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BIOABioAge Labs Inc. | 6.21 | -0.80% | $285.02M | vs FULC |
| ABEOAbeona Therapeutics Inc. | 4.96 | -2.36% | $283.63M | vs FULC |
| RCKTRocket Pharmaceuticals Inc. | 2.63 | +3.75% | $288.71M | vs FULC |
| BBOTBridgeBio Oncology Therapeutics Inc. | 3.42 | -0.58% | $274.20M | vs FULC |
| CYPHCypherpunk Technologies Inc. | 2.81 | -7.87% | $302.82M | vs FULC |
| BNTCBenitec Biopharma Inc. | 8.75 | -2.67% | $305.22M | vs FULC |
| CATXPerspective Therapeutics Inc. | 2.71 | +10.16% | $309.35M | vs FULC |
| PRLDPrelude Therapeutics Incorporated | 3.88 | +1.31% | $309.64M | vs FULC |
Indexes, lists and sector
Fulcrum Therapeutics stock FAQ
What is Fulcrum Therapeutics's stock price today?
FULC last traded at $3.75 as of Oct 8, 4:00 PM EDT, up 2.18% on the day. Prices are delayed at least 15 minutes.
When is Fulcrum Therapeutics's next earnings date?
Fulcrum Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.10.
Who is Fulcrum Therapeutics's CEO?
Mr. Alexander C. Sapir is the chief executive officer of Fulcrum Therapeutics Inc., which has about 9 employees.
What is the FULC 52-week high?
The 52-week high for FULC is $15.74 and the 52-week low is $2.83. The stock is currently 76.2% below its high.